Clinical Trials Logo

Epstein-Barr Virus Infections clinical trials

View clinical trials related to Epstein-Barr Virus Infections.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06131489 Not yet recruiting - Clinical trials for Hemophagocytic Lymphohistiocytosis

Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement

Start date: December 1, 2023
Phase:
Study type: Observational

EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.

NCT ID: NCT06075927 Not yet recruiting - Clinical trials for Stem Cell Transplant

Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT

Start date: November 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety and tolerability of partial HLA-matched VSTs against both CMV and EBV viruses in recipients of allogeneic hematopoietic stem cells with refractory viral infections (CMV and/or EBV). Preliminary evaluation of the efficacy of partial HLA-matched VSTs against both CMV and EBV viruses in recipients of allogeneic hematopoietic stem cells with refractory viral infections (CMV and/or EBV); To monitor the duration and expansion of multi-virus VSTs cells after infusion.

NCT ID: NCT05970627 Not yet recruiting - Clinical trials for Adenocarcinoma of the Stomach

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Start date: July 28, 2023
Phase: Phase 2
Study type: Interventional

This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative SOX combined with toripalimab in participants with Epstein-Barr Virus-associated locally advanced gastric or esophagogastric junction adenocarcinoma.

NCT ID: NCT05775705 Not yet recruiting - Lymphoma Clinical Trials

L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

Start date: August 1, 2023
Phase: Phase 3
Study type: Interventional

The efficacy and safety of L-DEP (PEG-aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) regimen combined with PD-1 Antibody an induction therapy for Epstein-Barr virus (EBV)-positive lymphoma-associated hemophagocytic lymphohistiocytosis.

NCT ID: NCT04690036 Not yet recruiting - Transplant Clinical Trials

PD-1 Antibody for Reactive EBV After BMT

Start date: July 1, 2021
Phase: Early Phase 1
Study type: Interventional

PD-1 antibody for reactivation of EBV after transplantation in patients with CAEBV/EBV-HLH